MEDX Horizon Kinetics Medical ETF

ETF on NASDAQ (US) · Actively managed · Listing

Form N-PORT Jun 30, 2026 vs Mar 31, 2026 Filed with the SEC Aug 26, 2026
Book +5% $18.5M → $19.4M
Line items (Mar 31, 2026: 33) 33
In top 10 71%
Largest holding: Eli Lilly and Company ($3.52M) 18.1%
Portfolio date Jun 30, 2026
New / increased 0 / 0
Reduced / closed 30 / 0
Unchanged 2
−5%

Most notable sale · Eli Lilly and Company

Eli Lilly and Company cut by 5%

Shares went from 3,077 to 2,936 ($2.83M → $3.52M). Now 18.1% of the portfolio. Estimated trade $169K.

Largest holding: Eli Lilly and Company, cut 5%, 2,936 shares ($3.52M).

Eli Lilly and Company: 18.1% US BANK MMDA - USBGFS 7: 9.0% AbbVie Inc.: 8.7% Novartis AG: 6.8% Johnson & Johnson: 5.5% Alkermes plc: 5.4% AstraZeneca: 4.9% Ionis Pharmaceuticals, Inc.: 4.5% Bristol-Myers Squibb Company: 4.3% Merck & Company, Inc.: 3.9% The other 23 positions: 28.9% $19.4M Holdings value
Current positions Top 10 % of book
Eli Lilly and Company LLY $3.52M · −5% sh 18.1%
US BANK MMDA - USBGFS 7 USBGFS7 $1.75M · −4% units 9.0%
AbbVie Inc. ABBV $1.69M · −5% sh 8.7%
Novartis AG NVS $1.31M · −5% sh 6.8%
Johnson & Johnson JNJ $1.07M · −5% sh 5.5%
Alkermes plc ALKS $1.05M · −5% sh 5.4%
AstraZeneca AZN $951K · −5% sh 4.9%
Ionis Pharmaceuticals, Inc. IONS $865K · −5% sh 4.5%
Bristol-Myers Squibb Company BMY $844K · −5% sh 4.3%
Merck & Company, Inc. MRK $755K · −5% sh 3.9%

Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against Mar 31, 2026.

Healthcare: 89.6% Consumer Defensive: 0.6% Unclassified: 9.8% 2 sectors
Sectors % of holdings value
Healthcare 89.6%
Consumer Defensive 0.6%
Unclassified 9.8%
Drug Manufacturers - General: 57.9% Biotechnology: 31.3% Household & Personal Products: 0.6% Medical Devices: 0.4% Unclassified: 9.8% 4 industries
Industries % of holdings value
Drug Manufacturers - General 57.9%
Biotechnology 31.3%
Household & Personal Products 0.6%
Medical Devices 0.4%
Unclassified 9.8%
Initiations 0 Value
None this period.
Increases 0 Change
None this period.
Reductions 30 Change
Eli Lilly and Company LLY $2.83M → $3.52M −5%
AbbVie Inc. ABBV $1.53M → $1.69M −5%
Novartis AG NVS $1.34M → $1.31M −5%
Johnson & Johnson JNJ $1.08M → $1.07M −5%
Alkermes plc ALKS $746K → $1.05M −5%
AstraZeneca AZN $1.04M → $951K −5%
Ionis Pharmaceuticals, Inc. IONS $858K → $865K −5%
Bristol-Myers Squibb Company BMY $931K → $844K −5%
Merck & Company, Inc. MRK $740K → $755K −5%
Amgen Inc. AMGN $760K → $747K −5%
Alnylam Pharmaceuticals, Inc. ALNY $752K → $653K −5%
Biogen Inc. BIIB $524K → $589K −5%
Terminations 0 Change
None this period.

Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Jun 30, 2026 (Form N-PORT) vs the portfolio of Mar 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

Horizon Kinetics Medical ETF ("Medical ETF" or the "Fund") seeks to provide long-term growth of capital.

Principal investment strategies

The Fund is an actively managed exchange-traded fund ("ETF") that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks (such as American Depositary Receipts ("ADRs"), Global Depositary Receipts ("GDRs") and International Depositary Receipts ("IDRs")) of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries, generally, with an emphasis toward companies engaged in cancer research and drug development, such as pharmaceutical development companies, surgical and medical instrument manufacturers and developers, pharmaceutical manufacturers, and biotech and medical research companies. These types of companies derive at least 50% of their revenue from such activities. The Fund also may invest in other ETFs and purchase and write options for hedging purposes and/or direct investment. In addition, the Fund may purchase or engage in short sales of certain leveraged or inverse ETFs. The Fund may invest up to 20% of its total assets in convertible and non-convertible debt securities rated below investment grade, also known as junk bonds, or unrated securities that Horizon Kinetics Asset Management LLC, the Fund's investment adviser (the "Adviser"), has determined to be of comparable quality. 2 The Adviser selects portfolio securities by evaluating a company's positioning and the resources that it currently expends on research and development, looking for a significant percentage, or large amount, of capital invested into research and treatment of cancer and other diseases. The Adviser also considers a company's fundamentals by reviewing its balance sheets, corporate revenues, earnings and dividends. The Adviser also considers at the amount of capital a company spends on research and development because the Adviser believes that such expenditures frequently have significant bearing on future growth. The Fund may invest in companies of any size, including small and medium-size companies. Additionally, the Fund may participate in securities lending arrangements up to 33 1/3% of the securities in its portfolio with brokers, dealers, and financial institutions (but not individuals) to seek to increase the return on its portfolio. Decisions to sell the Fund's portfolio holdings are generally triggered by either adequate value being achieved, as determined by the Adviser, or an adverse change in a company's operating performance or a deterioration of the company's business model. A sell trigger also may occur if the Adviser discovers a new investment opportunity that it believes is more compelling and represents a greater risk reward profile than other investment(s) held by the Fund. The Fund may maintain during a temporary period of abnormal conditions, a significant portion of its total assets in cash and securities, generally considered to be cash and cash equivalents, including, but not limited to: high quality, U.S. short-term debt securities and money market instruments. The Adviser will invest in such short-term cash positions to the extent the Adviser is unable to find sufficient investments meeting its criteria and when the Adviser believes the purchase of additional equity securities would not further the investment objective of the Fund during such periods of time. Additionally, to respond to adverse market, economic, political or other conditions, which may persist for short or long periods of time, the Fund may invest up to 100% of its assets in the types of high quality, U.S. short-term debt securities and money market instruments described above.

Management and Contact

Adviser
Horizon Kinetics Asset Management, LLC
Portfolio managers

Peter B. Doyle, Co-Founder and Co-Chief Executive Officer, has been a portfolio manager of the Fund since January 2023 and was a Portfolio Manager of the Predecessor Fund since its inception in September 1999 through the Reorganization Date.

Steven Tuen, Portfolio Manager, James Davolos, Portfolio Manager, and Brandon Colavita, Portfolio Manager, have been portfolio managers of the Fund since April 2026.

Phone
1-800-617-0004

Track Record as of Dec 31, 2025

1 Year 5 Years 10 Years Since Inception
Return Before Taxes 28.45% 5.80% 5.67% 8.47%
Return After Taxes on Distributions 28.08% 5.23% 4.53% 7.70%
Return After Taxes on Distributions and Sale of Shares 17.11% 4.46% 4.24% 7.20%
S&P 500® TR Index (reflects no deduction for fees, expenses, or taxes) 17.88% 14.42% 14.82% 8.57%
S&P 500® TR Index(reflects no deduction for fees, expenses, or taxes) 17.88% 14.42% 14.82% 8.57%

Holdings as of Jun 30, 2026

33 lines, 30 linked, weights sum to 101.83% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
Eli Lilly & Co LLY US5324571083 Equity 2,936 −141 18.46% $ 3.522M
US BANK MMDA - USBGFS 7
USBGFS7 Money market 1,752,681.13 −68,123.34 9.19% $ 1.753M
AbbVie Inc ABBV US00287Y1091 Equity 6,712 −322 8.85% $ 1.689M
Novartis AG NVS US66987V1098 Equity 8,388 −403 6.89% $ 1.315M
Johnson & Johnson JNJ US4781601046 Equity 4,200 −201 5.59% $ 1.067M
Alkermes PLC ALKS IE00B56GVS15 Equity 20,132 −967 5.53% $ 1.055M
AstraZeneca PLC AZN GB0009895292 Equity 5,015 −241 4.98% $ 950.944K
Ionis Pharmaceuticals Inc IONS US4622221004 Equity 10,904 −524 4.53% $ 864.578K
Bristol-Myers Squibb Co BMY US1101221083 Equity 14,644 −704 4.42% $ 843.787K
Merck & Co Inc MRK US58933Y1055 Equity 5,872 −282 3.96% $ 754.552K
Amgen Inc AMGN US0311621009 Equity 2,062 −99 3.91% $ 746.691K
Alnylam Pharmaceuticals Inc ALNY US02043Q1076 Equity 2,168 −104 3.42% $ 652.633K
Biogen Inc BIIB US09062X1037 Equity 2,726 −131 3.09% $ 588.98K
Pfizer Inc PFE US7170811035 Equity 22,648 −1,088 2.86% $ 545.364K
GSK PLC GSK US37733W2044 Equity 9,846 −473 2.71% $ 516.127K
CRISPR Therapeutics AG CRSP CH0334081137 Equity 9,228 −443 2.64% $ 503.295K
Regeneron Pharmaceuticals Inc REGN US75886F1075 Equity 630 −30 2.06% $ 392.83K
Beam Therapeutics Inc BEAM US07373V1052 Equity 8,388 −403 1.51% $ 287.876K
Galectin Therapeutics Inc GALT US3632252025 Equity 46,968 −2,258 1.14% $ 217.932K
Intellia Therapeutics Inc NTLA US45826J1051 Equity 12,584 −604 1.12% $ 212.921K
Sandoz Group AG
SDZNY US7999261008 Equity 1,680 −80 0.80% $ 152.023K
Replimune Group Inc REPL US76029N1063 Equity 12,584 −604 0.73% $ 139.305K
Vanda Pharmaceuticals Inc VNDA US9216591084 Equity 22,648 −1,088 0.73% $ 138.606K
Haleon PLC HLN US4055521003 Equity 12,309 −591 0.60% $ 114.843K
Lantern Pharma Inc LTRN US51654W1018 Equity 25,164 −1,209 0.55% $ 104.934K
Editas Medicine Inc EDIT US28106W1036 Equity 27,680 −1,330 0.47% $ 89.683K
GE HealthCare Technologies Inc GEHC US36266G1076 Equity 840 −40 0.28% $ 53.768K
Bicycle Therapeutics PLC BCYC US0887861088 Equity 12,584 −604 0.28% $ 53.356K
Viatris Inc VTRS US92556V1061 Equity 3,122 −150 0.26% $ 49.577K
Allogene Therapeutics Inc ALLO US0197701065 Equity 16,776 −806 0.18% $ 34.894K
Pacific Biosciences of Califor PACB US69404D1081 Equity 10,068 −483 0.09% $ 16.914K
Decoy Therapeutics Inc DCOY US79400X6022 Equity 20.75 0 0.00% $ 149.19
Pathos AI Inc
2368714D Equity 23,992 0 0.00% $ 0.00

Trades Mar 31, 2026 to Jun 30, 2026

Holding Ticker Action Before After Change Value
Eli Lilly & Co LLY Sold 3,077 2,936 −141 $ -169.12K
AbbVie Inc ABBV Sold 7,034 6,712 −322 $ -81.028K
Novartis AG NVS Sold 8,791 8,388 −403 $ -63.158K
Johnson & Johnson JNJ Sold 4,401 4,200 −201 $ -51.048K
Alkermes PLC ALKS Sold 21,099 20,132 −967 $ -50.666K
AstraZeneca PLC AZN Sold 5,256 5,015 −241 $ -45.698K
Ionis Pharmaceuticals Inc IONS Sold 11,428 10,904 −524 $ -41.548K
Bristol-Myers Squibb Co BMY Sold 15,348 14,644 −704 $ -40.564K
Merck & Co Inc MRK Sold 6,154 5,872 −282 $ -36.237K
Amgen Inc AMGN Sold 2,161 2,062 −99 $ -35.85K
Alnylam Pharmaceuticals Inc ALNY Sold 2,272 2,168 −104 $ -31.307K
Biogen Inc BIIB Sold 2,857 2,726 −131 $ -28.304K
Pfizer Inc PFE Sold 23,736 22,648 −1,088 $ -26.199K
GSK PLC GSK Sold 10,319 9,846 −473 $ -24.795K
CRISPR Therapeutics AG CRSP Sold 9,671 9,228 −443 $ -24.161K
Regeneron Pharmaceuticals Inc REGN Sold 660 630 −30 $ -18.706K
Beam Therapeutics Inc BEAM Sold 8,791 8,388 −403 $ -13.831K
Galectin Therapeutics Inc GALT Sold 49,226 46,968 −2,258 $ -10.477K
Intellia Therapeutics Inc NTLA Sold 13,188 12,584 −604 $ -10.22K
Sandoz Group AG
SDZNY Sold 1,760 1,680 −80 $ -7,239.20
Replimune Group Inc REPL Sold 13,188 12,584 −604 $ -6,686.28
Vanda Pharmaceuticals Inc VNDA Sold 23,736 22,648 −1,088 $ -6,658.56
Haleon PLC HLN Sold 12,900 12,309 −591 $ -5,514.03
Lantern Pharma Inc LTRN Sold 26,373 25,164 −1,209 $ -5,041.53
Editas Medicine Inc EDIT Sold 29,010 27,680 −1,330 $ -4,309.20
Bicycle Therapeutics PLC BCYC Sold 13,188 12,584 −604 $ -2,560.96
GE HealthCare Technologies Inc GEHC Sold 880 840 −40 $ -2,560.40
Viatris Inc VTRS Sold 3,272 3,122 −150 $ -2,382.00
Allogene Therapeutics Inc ALLO Sold 17,582 16,776 −806 $ -1,676.48
Pacific Biosciences of Califor PACB Sold 10,551 10,068 −483 $ -811.44

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up